GET DAILY SIGNALSCentury Therapeutics (IPSC) Analyst Price Targets Suggest +245% Upside Potential
Key Takeaways
- The central $5.00 stock price target is the arithmetic mean of five verified analyst price targets, which average roughly $5.12 and are rounded to $5.00 for readability.
- Individual targets range widely, from $2.00 (Leerink Partners) to $8.00 (Mizuho), reflecting sharply divided views on a clinical-stage biotech with no approved products.
- At the latest verified close of $1.45, reaching $5.00 would require an upside of about 245% — a very large move relative to current levels.
- The strongest supporting factor is Century Therapeutics' (NASDAQ: IPSC) allogeneic iPSC platform and lead candidate CNTY-813 for type 1 diabetes, which bullish analysts argue is underappreciated.
- The biggest risks are a lack of near-term clinical catalysts, ongoing cash burn, and heavy reliance on preclinical-stage programs after the company de-prioritized its prior lead asset.
- Readers can find more on the company's Major News, Today's Price Move, Forecast, and Earnings.
- For automated market scanning and signal ideas, explore Trending AI Robots.
Analyst Price Targets and Consensus View
Century Therapeutics, Inc. (NASDAQ: IPSC) is a clinical-stage biotechnology company developing "off-the-shelf" allogeneic cell therapies derived from induced pluripotent stem cells (iPSCs), primarily for autoimmune diseases such as type 1 diabetes and for cancer. I reviewed five verifiable, current analyst price targets: Mizuho (Salim Syed) at $8.00, Clear Street (William Maughan) at $6.60, H.C. Wainwright at $5.00, Piper Sandler (Edward Tenthoff) at $4.00, and Leerink Partners (Daina Graybosch) at $2.00. The simple average is about $5.12, which rounds to the $5.00 central target used here. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The roughly $2.00-to-$8.00 range is unusually wide, reflecting genuine disagreement. Bulls, including Mizuho and Clear Street, emphasize the pipeline's optionality and the potential of lead candidate CNTY-813. Leerink's cautious $2.00 target, set when it downgraded the stock to Market Perform, stems from the company's decision to de-prioritize CNTY-101, which the firm said leaves limited "value-inflecting clinical catalysts" in the near term. No individual target should be treated as a guarantee, and the mean is not an officially published consensus figure.
Current Market Position and Path Toward the Target
The stock's latest verified close was $1.45, giving Century Therapeutics a market capitalization near $260 million. Reaching $5.00 would require a gain of about 245%, a very large move for any equity and one that would likely require meaningful clinical data, financing, or partnership news rather than incremental trading momentum alone. The shares have been highly volatile, trading within a 52-week range of roughly $0.44 to $3.04, and remain far below their early-2026 highs.
What Could Support a Move Toward the Target
- CNTY-813, an iPSC-derived beta islet cell therapy for type 1 diabetes, is the pipeline's centerpiece and a key driver of bullish analyst price targets.
- Clear Street has noted a private placement that extends the company's cash runway, reducing near-term dilution risk.
- The allogeneic, "off-the-shelf" approach addresses manufacturing and cost limits of first-generation cell therapies, a potential strategic advantage if validated clinically.
- A return of risk appetite for small-cap biotechnology and positive sector sentiment could amplify any catalyst-driven repricing.
What Could Prevent the Target From Being Reached
- The company is pre-revenue from products and loss-making, relying on clinical and preclinical progress to justify a higher valuation.
- De-prioritizing CNTY-101 removed a nearer-term clinical catalyst, pushing value inflection further out.
- Continued cash consumption may necessitate future financing, which can dilute existing shareholders and pressure the share price.
- Clinical-stage biotechs face binary outcomes: disappointing trial data or regulatory setbacks can rapidly compress valuations regardless of analyst targets.
Technical Levels and Market Structure
The shares trade near the lower end of a wide range, with the 52-week low around $0.44 and the 52-week high near $3.04. The $2.00 level, where Leerink places its target, also represents a notable round-number resistance area, while a decisive recovery above the prior $3.04 high would mark the first durable structural breakout on any path toward $5.00. These levels are psychological and historical markers rather than predictive thresholds.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a research horizon of about 12 months, though the exact horizon can vary by firm and is not always disclosed. Investors should monitor clinical data updates and regulatory milestones for CNTY-813 and other pipeline candidates, quarterly cash and runway disclosures, any new partnership or licensing arrangements, analyst target revisions, and broader biotech sector sentiment. Given the stock's beta and volatility, financing announcements and insider activity are also worth watching. From what I see, this is important because timing can shift quickly in this space.
Exploring AI Daily Buy/Sell Signals for Efficient Tracking
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile, event-driven name like Century Therapeutics, such tools can help traders discover opportunities, monitor existing positions, and spot emerging trend changes more efficiently than manual review. Traders looking for a more systematic way to track changing conditions can explore these signals as part of a broader research process.
Using Tickeron AI Tools in My Research Process
In my view, integrating AI-driven platforms into routine analysis helps surface patterns that might otherwise go unnoticed in fast-moving names like this one. I’ve found Tickeron’s suite particularly useful for cross-checking signals against analyst views and technical levels without spending hours on manual scans. It keeps the focus on data rather than noise, especially when evaluating clinical-stage biotechs with wide valuation ranges.
Final Assessment
The $5.00 central target reflects the arithmetic mean of five analyst price targets averaging about $5.12, spanning a wide $2.00-to-$8.00 range that signals genuine disagreement about Century Therapeutics' prospects. From a current price near $1.45, the required move of roughly 245% is very large and would almost certainly depend on clinical validation of CNTY-813, continued cash-runway management, and renewed investor appetite for early-stage biotech. The principal obstacles remain a sparse near-term catalyst calendar, ongoing losses, and the inherent binary risk of drug development. Analysts' bullish and cautious views diverge sharply, and no outcome — up or down — is assured; investors should weigh the pipeline opportunity against the financing and execution risks before forming their own view. I’m watching this closely as new data emerges.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for IPSC turns positive, indicating new upward trend
IPSC saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In 77 of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IPSC's RSI Indicator exited the oversold zone, 26 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for IPSC just turned positive on October 15, 2026. Looking at past instances where IPSC's MACD turned positive, the stock continued to rise in 42 of 52 cases over the following month. The odds of a continued upward trend are 81%.
Following a +19.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where IPSC advanced for three days, in 197 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
IPSC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 53 cases where IPSC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
The 50-day moving average for IPSC moved below the 200-day moving average on September 24, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IPSC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IPSC entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.130) is normal, around the industry mean (2.974). P/E Ratio (-1.559) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (1.824) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. IPSC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IPSC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology